GBT Global Blood Therapeutics Inc

Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September:

• 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET);
• Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and
• Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 1:05 p.m. ET.

The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.

About Global Blood TherapeuticsGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.

Contact Information: 
Myesha Lacy (investors)
GBT
650-351-4730
investor@globalbloodtx.com

Julie Normart (media)
Pure Communications
415-946-1087
media@globalbloodtx.com